Fair Value Calculator Check a stock
Research & Education

Ageas SA/NV Fair Value: AGS Stock Undervalued at €71

2026-07-17 · fairvalue-calculator.com
Dr. Peter Klein By Dr. Peter Klein, BA · Founder

Ageas SA/NV Fair Value Deep-Dive: Why AGS Looks Undervalued

Ageas SA/NV (AGS.BR), a leading Belgian diversified insurer, currently trades at EUR 71.05. Our comprehensive fair value assessment places the stock at EUR 106.37, pointing to +49.7% upside. With a Quality Score of 66/100, the company earns a clear "undervalued" verdict from our 21-model framework.

What Ageas SA/NV Does

Ageas operates across life and non-life insurance in Belgium and key international markets including the UK, Portugal, and Asia. It serves millions of customers with savings, protection, and property & casualty products. The group has built a solid track record of disciplined capital management and consistent dividend growth.

Why Our Models See Ageas SA/NV as Undervalued

Multiple valuation lenses converge on material undervaluation. The stock trades at a trailing P/E of approximately 7.8x while delivering attractive earnings growth targets under the Elevate27 plan (6-8% average EPS growth). Strong holding free cash flow ambitions exceeding €2.2 billion by 2027, combined with a forward dividend yield near 6%, support a higher intrinsic value than the market currently prices in. Recent capital deployment and market share gains in core domestic segments further bolster the case.

Analyst consensus targets sit in the EUR 68-80 range, yet our broader set of discounted cash flow, residual income, and peer-relative models point higher, reflecting the sustainability of Ageas's franchise and capital returns.

Key Valuation Drivers

  • Robust earnings momentum: Recent results and the Elevate27 strategy highlight disciplined execution and positive one-off items that support higher forward earnings.
  • Attractive shareholder returns: A history of growing dividends and share buybacks, with over €1.9 billion targeted for distribution by 2027.
  • International diversification: Exposure beyond Belgium reduces single-market risk while capturing growth in non-life and life segments.

Main Risks to Consider

  • Legacy finance exposures that could occasionally dilute results.
  • Sensitivity to interest rates and bond markets given the insurance investment book.
  • Regulatory changes or competitive pressures in European insurance markets.

These factors are already reflected in the current discount and our Quality Score of 66/100, which balances strengths in profitability and growth against certain legacy and cyclical risks.

💡 Theory is good, numbers are better. Get the fair value of any stock worldwide in seconds. Try it free →

Investors seeking a data-driven view can check ageas SA/NV on our free fair value calculator alongside 35,000+ other stocks and 21 valuation models.

Balanced Verdict on Ageas SA/NV

Ageas SA/NV combines a high-quality insurance franchise with an attractive valuation multiple. While near-term volatility around interest rates or legacy items remains possible, the gap between current price and our fair value of EUR 106.37 suggests the market is overly cautious. For long-term investors focused on income and moderate growth, the risk-reward profile appears compelling at current levels. This is not financial advice—always conduct your own research or consult a professional.

Frequently Asked Questions

Is Ageas SA/NV undervalued right now?

Yes, our models show Ageas SA/NV trading at a significant discount to fair value of €106.37 versus the current price of €71.05, implying nearly 50% upside potential.

What are the main risks for Ageas stock?

Key risks include legacy finance issues, interest rate sensitivity in its insurance book, and regulatory or market volatility in its core European operations.

When is the next Ageas earnings report?

Ageas is scheduled to report its next earnings on August 26, 2026, which will provide fresh insight into performance under the Elevate27 strategy.

Sources

Context gathered via live web search while writing this article:

Check the fair value of any stock worldwide
21 valuation models · 35,000+ stocks · evidence-based
Start free →

Not financial advice · No buy/sell recommendations · Past performance is not a guarantee of future results.